According to the Wall Street Journal, researchers from Johnson & Johnson, AstraZeneca and Oxford University are collaborating with other scientists to see if modifying their COVID-19 vaccine can reduce or eliminate the risk of rare but serious blood clots.
Teams from Johnson & Johnson, AstraZeneca, and Oxford University are working with outside scientists to possibly modify their COVID-19 vaccine to reduce or eliminate the risk of rare but dangerous blood clots associated with injections. The Wall Street Journal (The Wall Street Journal) The Daily reported on Tuesday, citing people familiar with the matter.
This research is still in its early stages, but “rapidly evolving clues about how clots form-driven in part by independent scientists in Europe, the United States, and Canada-are raising hopes of determining the cause, and may redesign AstraZeneca next time. The Lens Year”, the Wall Street Journal quoted some people close to the process as saying.
The newspaper said that it is not yet certain whether the two vaccines can be modified or whether it makes commercial sense.
A Johnson & Johnson spokesperson told The Wall Street Journal that the company supports “continuing research and analysis while working with medical experts and global health authorities.”
According to the Wall Street Journal, AstraZeneca stated that it “is actively working with regulatory agencies and the scientific community to understand these extremely rare coagulation events, including information to promote early diagnosis and intervention and appropriate treatment.”
In April, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention (CDC) called for the suspension of the use of Johnson & Johnson’s (J&J) COVID-19 vaccine because the vaccine is related to a rare case of severe thrombosis, but they cancelled the treatment of Johnson & Johnson ( J&J) the use of the COVID-19 vaccine. Stop temporarily after confirming that the benefits of the vaccine outweigh the risks.
The AstraZeneca vaccine has not yet been approved for use in the United States, but has been widely used in other parts of the world. According to the Wall Street Journal, regulatory agencies in the United Kingdom and Europe have been widely used, recommending that young people who are considered more likely to develop blood clots should be vaccinated with different COVID-19 vaccines.
In addition, the vaccines of Johnson & Johnson and AstraZeneca are under review for Guillain-Barré syndrome, a disease in which the immune system attacks the nerves. On Monday, US regulators added a warning to Johnson & Johnson vaccine, warning that the risk of the disease is small but will increase.
The CDC said in a statement on Monday that after 12.8 million doses of Johnson & Johnson’s COVID-19 injections in the United States, approximately 100 initial reports of Guillain-Barré syndrome have been detected.
European regulators have also recommended a similar warning that AstraZeneca’s COVID-19 vaccine may increase the risk of Guillain-Barré syndrome.